Mechanism of action

Sermorelin provides a GHRH-like stimulus to the pituitary growth hormone axis. This differs from supplying growth hormone (GH) itself: the experiment measures the gland's response to a releasing signal. In a placebo-controlled study involving five healthy volunteers, Losa et al. (1984) compared GRF fragments of different lengths, including GRF(1-29), and observed increased circulating GH. That finding demonstrates an endocrine response in the studied setting, not a universal response in people with impaired pituitary function. It also does not establish a sustained clinical outcome. Research on this axis must distinguish the releasing peptide, the amount of GH subsequently secreted and downstream measures such as insulin-like growth factor I. They are related measurements but are not interchangeable evidence of benefit.

State of evidence

Human evidence covers different populations and designs. Thorner et al. (1996) studied GHRH(1-29) in children with growth hormone deficiency in a multicenter open-label study: 110 children received treatment and 86 were eligible for efficacy analysis. Height velocity increased relative to baseline, but the study did not include a parallel placebo group. Vittone et al. (1997) studied 11 healthy older men for six weeks. Nocturnal GH secretion increased, while IGF-I, body weight and measured body composition did not change; selected strength measures improved. This small exploratory study cannot establish broad effects on aging. Regulatory history is also specific: the FDA's 2013 notice records earlier Geref approvals for diagnostic assessment and pediatric growth hormone deficiency, followed by withdrawal of both approvals in 2009. It states that withdrawal from sale was not for safety or effectiveness reasons. That determination does not turn every sermorelin preparation into an approved medicine or establish a present authorization.

Questions about the research

Is sermorelin the same as growth hormone?

No. Sermorelin is a fragment of the hormone that signals GH release. GH is a different hormone. A measurable increase in GH following a releasing signal does not by itself show a change in body composition, functional improvement or long-term clinical benefit. Each endpoint must be assessed separately.

Does the Geref history mean that a research product is approved?

No. The FDA record concerns named medicines, specific applications and historical indications. It also records withdrawal of those approvals. Approval history cannot be transferred to a different product, preparation or purpose. The 2013 determination about the reason for withdrawal from sale is not evidence of current authorization for a research product.

Can results from other GHRH analogues be attributed to sermorelin?

Only with an explicit explanation of the material studied. A substituted GHRH analogue, a longer fragment and GHRH(1-29)-amide are not automatically identical. Evidence should name the sequence or analogue and retain the original population and study design, rather than combine all GHRH research into one effectiveness claim.

Sources

1. Losa et al., Klin Wochenschr 1984DOI: 10.1007/BF01782473PMID: 6240568
2. Thorner et al., J Clin Endocrinol Metab 1996DOI: 10.1210/jcem.81.3.8772599PMID: 8772599
3. Vittone et al., Metabolism 1997DOI: 10.1016/S0026-0495(97)90174-8PMID: 9005976
4. FDA, Federal Register 2013, Geref withdrawal determination

Mechanism of action

Sermorelin provides a GHRH-like stimulus to the pituitary growth hormone axis. This differs from supplying growth hormone (GH) itself: the experiment measures the gland's response to a releasing signal. In a placebo-controlled study involving five healthy volunteers, Losa et al. (1984) compared GRF fragments of different lengths, including GRF(1-29), and observed increased circulating GH. That finding demonstrates an endocrine response in the studied setting, not a universal response in people with impaired pituitary function. It also does not establish a sustained clinical outcome. Research on this axis must distinguish the releasing peptide, the amount of GH subsequently secreted and downstream measures such as insulin-like growth factor I. They are related measurements but are not interchangeable evidence of benefit.

State of evidence

Human evidence covers different populations and designs. Thorner et al. (1996) studied GHRH(1-29) in children with growth hormone deficiency in a multicenter open-label study: 110 children received treatment and 86 were eligible for efficacy analysis. Height velocity increased relative to baseline, but the study did not include a parallel placebo group. Vittone et al. (1997) studied 11 healthy older men for six weeks. Nocturnal GH secretion increased, while IGF-I, body weight and measured body composition did not change; selected strength measures improved. This small exploratory study cannot establish broad effects on aging. Regulatory history is also specific: the FDA's 2013 notice records earlier Geref approvals for diagnostic assessment and pediatric growth hormone deficiency, followed by withdrawal of both approvals in 2009. It states that withdrawal from sale was not for safety or effectiveness reasons. That determination does not turn every sermorelin preparation into an approved medicine or establish a present authorization.

Questions about the research

Is sermorelin the same as growth hormone?

No. Sermorelin is a fragment of the hormone that signals GH release. GH is a different hormone. A measurable increase in GH following a releasing signal does not by itself show a change in body composition, functional improvement or long-term clinical benefit. Each endpoint must be assessed separately.

Does the Geref history mean that a research product is approved?

No. The FDA record concerns named medicines, specific applications and historical indications. It also records withdrawal of those approvals. Approval history cannot be transferred to a different product, preparation or purpose. The 2013 determination about the reason for withdrawal from sale is not evidence of current authorization for a research product.

Can results from other GHRH analogues be attributed to sermorelin?

Only with an explicit explanation of the material studied. A substituted GHRH analogue, a longer fragment and GHRH(1-29)-amide are not automatically identical. Evidence should name the sequence or analogue and retain the original population and study design, rather than combine all GHRH research into one effectiveness claim.

Sources

1. Losa et al., Klin Wochenschr 1984DOI: 10.1007/BF01782473PMID: 6240568
2. Thorner et al., J Clin Endocrinol Metab 1996DOI: 10.1210/jcem.81.3.8772599PMID: 8772599
3. Vittone et al., Metabolism 1997DOI: 10.1016/S0026-0495(97)90174-8PMID: 9005976
4. FDA, Federal Register 2013, Geref withdrawal determination